Ido2 Deficiency Exacerbates Motor Impairment and Reduces Aryl Hydrocarbon Receptor Activity through Decreased Kynurenine in a Chronic Demyelinating Mouse Model-Reference-Cited by-同舟云学术

Ido2 Deficiency Exacerbates Motor Impairment and Reduces Aryl Hydrocarbon Receptor Activity through Decreased Kynurenine in a Chronic Demyelinating Mouse Model

Published:2024-06-03 Issue: Volume: Page:
ISSN:0893-7648
Container-title:Molecular Neurobiology
language:en
Short-container-title:Mol Neurobiol

Author:

Kunisawa Kazuo,Hara Mitsuki,Yoshidomi Koyo,Kon Yuki,Yamamoto Yasuko,Fujigaki Suwako,Wulaer Bolati,Kosuge Aika,Tanabe Moeka,Saitoh Sei,Takahashi Kazuo,Saito Kuniaki,Nabeshima Toshitaka,Mouri Akihiro

Funder

Japan Society for the Promotion of Science

Japan Science and Technology Agency

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s12035-024-04263-9.pdf

Reference39 articles.

1. Shimizu T, Wisessmith W, Li J, Abe M, Sakimura K, Chetsawang B, Sahara Y, Tohyama K et al (2017) The balance between cathepsin C and cystatin F controls remyelination in the brain of Plp1-overexpressing mouse, a chronic demyelinating disease model. Glia 65(6):917–930. https://doi.org/10.1002/glia.23134

2. Weiner HL (2009) The challenge of multiple sclerosis: how do we cure a chronic heterogeneous disease? Ann Neurol 65(3):239–248. https://doi.org/10.1002/ana.21640

3. Lovelace MD, Varney B, Sundaram G, Franco NF, Ng ML, Pai S, Lim CK, Guillemin GJ et al (2016) Current Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis. Front Immunol 7:246. https://doi.org/10.3389/fimmu.2016.00246

4. Lovelace MD, Varney B, Sundaram G, Lennon MJ, Lim CK, Jacobs K, Guillemin GJ, Brew BJ (2017) Recent evidence for an expanded role of the kynurenine pathway of tryptophan metabolism in neurological diseases. Neuropharmacology 112(Pt B):373–388. https://doi.org/10.1016/j.neuropharm.2016.03.024

5. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, Boon T, Van den Eynde BJ (2003) Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med 9(10):1269–1274. https://doi.org/10.1038/nm934